AZN vs VSTM: Which Is the Better Buy in 2026?

Last updated October 2026

Short answer

AZN is the larger of the two ($256.54B market cap): the incumbent the market prices for continued execution (14.58x forward earnings, beta 0.21). VSTM is the smaller challenger ($783.37M), priced similarly on forward earnings (-7.09x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

AZN vs VSTM: the tie-breaker metrics

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Metric	AZN	VSTM	What it tells you
Market cap	$256.54B	$783.37M	Size. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E	14.58	-7.09	Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta	0.21	0.39	Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range	20% of range	71% of range	Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book	5.10	15.67	How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how AZN and VSTM affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AZN and VSTM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AZN and VSTM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does AstraZeneca (AZN) do?

AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. It develops and sells prescription medicines across four main areas: oncology (its biggest engine), cardiovascular-renal-metabolism, respiratory and immunology, and rare disease through Alexion, which it acquired in 2021. Flagship products include the cancer drugs Tagrisso, Imfinzi, Calquence, Lynparza (partnered with Merck) and Enhertu (partnered with Daiichi Sankyo), plus the diabetes and heart-failure drug Farxiga and rare-disease therapies like Ultomiris and Soliris. In 2025 the company reported total revenue of about $58.7 billion, up roughly 9%, and it has set a public ambition to grow that to $80 billion by 2030, with about half expected to come from the United States.

Full AZN guide

What does Verastem Oncology (VSTM) do?

Verastem Oncology is a Needham, Massachusetts biotech focused on the RAS/MAPK pathway, the signaling chain that is mutated in roughly a third of human cancers. Its first approved product, AVMAPKI FAKZYNJA CO-PACK (avutometinib, a RAF/MEK inhibitor, taken with defactinib, a FAK inhibitor), won FDA accelerated approval in May 2025 for adults with recurrent KRAS-mutated low-grade serous ovarian cancer (LGSOC) who have had prior systemic therapy. Product sales are now the main source of revenue. The company also collects occasional milestone payments from Secura Bio, which bought its earlier drug COPIKTRA, and it has a royalty financing deal with Oberland Capital tied to future product sales.

Full VSTM guide

AZN vs VSTM: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

AZN drivers: Oncology franchise and the $80 billion ambition; Deep late-stage pipeline.
VSTM drivers: VS-7375 in KRAS G12D pancreatic cancer; The ovarian cancer launch ramp.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. For VSTM, the clearest risk is that VS-7375's early results do not hold up.

AZN or VSTM: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AZN if you believe its drivers more; VSTM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AZN and VSTM guides.

AZN vs VSTM: the full fundamentals

AZN. AstraZeneca trades at about 25 times trailing reported earnings but about 14.6 times forward earnings, a gap that reflects heavy amortisation and one-off charges in reported profit and consensus for 2026 core EPS near $10.05 rising to about $11.34 in 2027. After falling about 9.5% in 2026, the forward multiple sits near the low end of where a growth-oriented large-cap pharma usually trades, so the valuation now reflects more caution about the 2032 patent cliff than enthusiasm for the $80 billion 2030 goal. Q3 2026 results arrive October 30, with consensus revenue near $16.0 billion. Figures are approximate and tied to the asOf date; confirm live numbers before acting.

VSTM. At roughly $1 billion in market value against ~$87.5 million of trailing revenue, about 12 times sales, the market is pricing Verastem mostly on VS-7375 rather than on its ovarian franchise. Price-to-earnings multiples do not apply while the company loses money, and the trailing revenue figure is flattered by a one-time $15 million milestone. The most useful lenses are cash runway, the pace of product sales growth, and how the pipeline compares with rivals. The October offering added ~30.9 million shares plus pre-funded warrants, a meaningful increase on a share base of roughly 100 million earlier in 2026.

Headline figures (approximate, October 2026): AZN shows revenue (ttm) About $61.4 billion; Q2 2026 revenue about $15.4 billion, up roughly 6% year over year, net income (ttm) About $10.5 billion, a net margin near 17%, with gross margin near 82%, eps Q2 2026 EPS $1.32 vs about $1.25 expected; trailing reported EPS about $6.69, p/e About 25x trailing reported earnings, about 14.6x forward; VSTM shows revenue (ttm) ~$87.5M (incl. $15M COPIKTRA milestone), product revenue (q2 2026) ~$25.1M (Q1: ~$18.7M), net loss (q2 2026) ~$34.7M ($0.35/share), cash (june 30, 2026, pre-offering) ~$136.4M (~$201M pro forma).

The bottom line: AZN vs VSTM

AZN and VSTM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AZN and VSTM exposure against your real portfolio. It is not an investment adviser.

Wondering how AZN or VSTM fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Investing in AstraZeneca with AI

Connect the broker you already use and ask Walnut's AI how AZN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does AZN fit me?

FAQ

What is the difference between AZN and VSTM?

AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. Verastem Oncology is a Needham, Massachusetts biotech focused on the RAS/MAPK pathway, the signaling chain that is mutated in roughly a third of human cancers. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is AZN or VSTM the better stock?

Neither is universally better. AZN is the larger incumbent; VSTM is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, AZN or VSTM?

On forward P/E (as of October 2026), AZN trades at 14.58x and VSTM at -7.09x, so VSTM is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both AZN and VSTM?

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of AZN vs VSTM?

AZN: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. Generic and biosimilar erosion is already visible, with first generics to Farxiga cleared in 2026. Pipeline risk is constant, since late-stage trial failures such as a disappointing AVANZAR result can erase billions in expected value quickly. China, about a tenth of revenue, carries added uncertainty after the company's former China head was indicted in a compliance case that drew investor lawsuits. Drug pricing policy, US tariffs and currency swings add further volatility, and the balance sheet carries about $32 billion of debt against about $5 billion of cash. As a large-cap pharma the stock can still fall sharply on a single disappointing readout or regulatory decision, as its roughly 22% slide from the 52-week high shows. VSTM: The clearest risk is that VS-7375's early results do not hold up. The pancreatic response rate comes from 22 patients in a single-arm study with about six months of median follow-up, and response rates often fall, and durability often disappoints, as trials grow and move into randomized Phase 3 designs. Competition is a second risk: Revolution Medicines is running Phase 3 trials of RAS inhibitors in pancreatic cancer, and Eli Lilly, AstraZeneca, Boehringer Ingelheim and several Chinese biotechs have G12D or pan-RAS programs, many backed by far larger budgets. Third, Verastem lost ~$34.7 million in Q2 2026 and ~$200 million over the trailing twelve months, and three Phase 3 programs would be expensive, so further equity raises are plausible. Fourth, its ovarian product holds accelerated approval, which depends on the RAMP 301 confirmatory trial due in mid-2027. The Oberland royalty deal also gives up a share of future product revenue. Finally, VS-7375 is in-licensed from GenFleet, so milestones and royalties owed to the licensor reduce the economics, and the stock has swung between ~$3.43 and ~$10.82 over the past year.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AZN or VSTM; figures are approximate and dated (as of October 2026). Verify current data before investing.